세계의 말초 동맥 질환 시장 보고서 : 유형, 최종사용자, 지역별(2024-2032년)

The global peripheral artery disease market size reached US$ 4.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 7.4 Billion by 2032, exhibiting a growth rate (CAGR) of 5.2% during 2024-2032.

Peripheral artery disease (PAD) is a cardiovascular disorder wherein constricted arteries restrict blood flow to the limbs. It results in hair loss, leg numbness, feet or toe sores, painful cramps in hips and thighs, coldness and weak pulse in legs, and erectile dysfunction among men. It is caused when a plaque, also known as atherosclerosis, develops in leg arteries that carry oxygen and nutrient-rich blood from the heart to the arms and legs. It is diagnosed using the ankle-brachial index, ultrasound scan, angiography, blood tests, doppler and ultrasound (duplex) imaging, computed tomographic angiography (CT), and magnetic resonance angiography (MRA).

Peripheral Artery Disease Market Trends:

At present, there is a rise in the geriatric population across the globe. This, along with changing lifestyles of individuals, increasing adoption of unhealthy dietary patterns, alcoholism, and obesity on account of lack of physical activities, represents one of the key factors driving the market. Moreover, there is an increase in the adoption of minimally invasive surgeries (MIS) due to less postoperative pain, fewer operative and major postoperative complications, shortened hospital stay, faster recovery times, and less stress on the immune system. This, coupled with the expanding healthcare industry, is propelling the growth of the market. In addition, governments of several countries are undertaking initiatives to spread awareness about the benefits of PAD devices, which is positively influencing the market. Besides this, the rising prevalence of cardiac diseases among individuals around the world is offering lucrative growth opportunities to industry investors. Furthermore, key market players are focusing on mergers and acquisitions (M&A) to strengthen PAD treatment capabilities. These players are also focusing on various developmental strategies, which are projected to bolster their overall profitability.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global peripheral artery disease market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type and end user.

Breakup by Type:

Peripheral Angioplasty Balloons

Peripheral Stents

Peripheral Catheters

Inferior Vena Cava (IVC) Filters

Plaque Modification Devices

Hemodynamic Flow Alteration Devices

Peripheral Accessories

Breakup by End User:

Hospitals

Specialty Clinics

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, AngioDynamics, B. Braun Melsungen AG, Becton Dickinson and Company, Biotronik SE & Co. KG, Boston Scientific Corporation, Cardinal Health Inc., Cook Medical LLC, Koninklijke Philips N.V., Medtronic plc and Terumo Corporation.

Key Questions Answered in This Report

• 1. How big is the global peripheral artery disease market?
• 2. What is the expected growth rate of the global peripheral artery disease market during 2024-2032?
• 3. What are the key factors driving the global peripheral artery disease market?
• 4. What has been the impact of COVID-19 on the global peripheral artery disease market?
• 5. What is the breakup of the global peripheral artery disease market based on the type?
• 6. What are the key regions in the global peripheral artery disease market?
• 7. Who are the key players/companies in the global peripheral artery disease market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Peripheral Artery Disease Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Peripheral Angioplasty Balloons
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Peripheral Stents
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Peripheral Catheters
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Inferior Vena Cava (IVC) Filters
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Plaque Modification Devices
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast
• 6.6 Hemodynamic Flow Alteration Devices
  • 6.6.1 Market Trends
  • 6.6.2 Market Forecast
• 6.7 Peripheral Accessories
  • 6.7.1 Market Trends
  • 6.7.2 Market Forecast

7 Market Breakup by End User

• 7.1 Hospitals
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Specialty Clinics
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Others
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Region

• 8.1 North America
  • 8.1.1 United States
    • 8.1.1.1 Market Trends
    • 8.1.1.2 Market Forecast
  • 8.1.2 Canada
    • 8.1.2.1 Market Trends
    • 8.1.2.2 Market Forecast
• 8.2 Asia-Pacific
  • 8.2.1 China
    • 8.2.1.1 Market Trends
    • 8.2.1.2 Market Forecast
  • 8.2.2 Japan
    • 8.2.2.1 Market Trends
    • 8.2.2.2 Market Forecast
  • 8.2.3 India
    • 8.2.3.1 Market Trends
    • 8.2.3.2 Market Forecast
  • 8.2.4 South Korea
    • 8.2.4.1 Market Trends
    • 8.2.4.2 Market Forecast
  • 8.2.5 Australia
    • 8.2.5.1 Market Trends
    • 8.2.5.2 Market Forecast
  • 8.2.6 Indonesia
    • 8.2.6.1 Market Trends
    • 8.2.6.2 Market Forecast
  • 8.2.7 Others
    • 8.2.7.1 Market Trends
    • 8.2.7.2 Market Forecast
• 8.3 Europe
  • 8.3.1 Germany
    • 8.3.1.1 Market Trends
    • 8.3.1.2 Market Forecast
  • 8.3.2 France
    • 8.3.2.1 Market Trends
    • 8.3.2.2 Market Forecast
  • 8.3.3 United Kingdom
    • 8.3.3.1 Market Trends
    • 8.3.3.2 Market Forecast
  • 8.3.4 Italy
    • 8.3.4.1 Market Trends
    • 8.3.4.2 Market Forecast
  • 8.3.5 Spain
    • 8.3.5.1 Market Trends
    • 8.3.5.2 Market Forecast
  • 8.3.6 Russia
    • 8.3.6.1 Market Trends
    • 8.3.6.2 Market Forecast
  • 8.3.7 Others
    • 8.3.7.1 Market Trends
    • 8.3.7.2 Market Forecast
• 8.4 Latin America
  • 8.4.1 Brazil
    • 8.4.1.1 Market Trends
    • 8.4.1.2 Market Forecast
  • 8.4.2 Mexico
    • 8.4.2.1 Market Trends
    • 8.4.2.2 Market Forecast
  • 8.4.3 Others
    • 8.4.3.1 Market Trends
    • 8.4.3.2 Market Forecast
• 8.5 Middle East and Africa
  • 8.5.1 Market Trends
  • 8.5.2 Market Breakup by Country
  • 8.5.3 Market Forecast

9 SWOT Analysis

• 9.1 Overview
• 9.2 Strengths
• 9.3 Weaknesses
• 9.4 Opportunities
• 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

• 11.1 Overview
• 11.2 Bargaining Power of Buyers
• 11.3 Bargaining Power of Suppliers
• 11.4 Degree of Competition
• 11.5 Threat of New Entrants
• 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

• 13.1 Market Structure
• 13.2 Key Players
• 13.3 Profiles of Key Players
  • 13.3.1 Abbott Laboratories
    • 13.3.1.1 Company Overview
    • 13.3.1.2 Product Portfolio
    • 13.3.1.3 Financials
    • 13.3.1.4 SWOT Analysis
  • 13.3.2 AngioDynamics
    • 13.3.2.1 Company Overview
    • 13.3.2.2 Product Portfolio
    • 13.3.2.3 Financials
    • 13.3.2.4 SWOT Analysis
  • 13.3.3 B. Braun Melsungen AG
    • 13.3.3.1 Company Overview
    • 13.3.3.2 Product Portfolio
    • 13.3.3.3 SWOT Analysis
  • 13.3.4 Becton Dickinson and Company
    • 13.3.4.1 Company Overview
    • 13.3.4.2 Product Portfolio
    • 13.3.4.3 Financials
    • 13.3.4.4 SWOT Analysis
  • 13.3.5 Biotronik SE & Co. KG
    • 13.3.5.1 Company Overview
    • 13.3.5.2 Product Portfolio
    • 13.3.5.3 SWOT Analysis
  • 13.3.6 Boston Scientific Corporation
    • 13.3.6.1 Company Overview
    • 13.3.6.2 Product Portfolio
    • 13.3.6.3 Financials
  • 13.3.7 Cardinal Health Inc.
    • 13.3.7.1 Company Overview
    • 13.3.7.2 Product Portfolio
    • 13.3.7.3 Financials
    • 13.3.7.4 SWOT Analysis
  • 13.3.8 Cook Medical LLC
    • 13.3.8.1 Company Overview
    • 13.3.8.2 Product Portfolio
    • 13.3.8.3 SWOT Analysis
  • 13.3.9 Koninklijke Philips N.V.
    • 13.3.9.1 Company Overview
    • 13.3.9.2 Product Portfolio
    • 13.3.9.3 Financials
    • 13.3.9.4 SWOT Analysis
  • 13.3.10 Medtronic plc
    • 13.3.10.1 Company Overview
    • 13.3.10.2 Product Portfolio
    • 13.3.10.3 Financials
    • 13.3.10.4 SWOT Analysis
  • 13.3.11 Terumo Corporation
    • 13.3.11.1 Company Overview
    • 13.3.11.2 Product Portfolio
    • 13.3.11.3 Financials
    • 13.3.11.4 SWOT Analysis